The US Food and Drug Administration (FDA) has approved BridgeBio Pharma’s Attruby (acoramidis), a near-complete (≥90%) stabiliser of Transthyretin (TTR).  It is approved for the treatment of adults with Transthyretin amyloid cardiomyopathy (ATTR-CM) to reduce cardiovascular death and cardiovascular-related hospitalisation.   The FDA approval is based on the ATTRibute-CM Phase III study, where Attruby significantly reduced […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!